Cognetivity Neurosciences Selected to Present Groundbreaking New Research Data at the Alzheimer’s Society Annual Conference 2019
New Research Provides Further Scientific Validation of the ICA Test’s Unique Capabilities in Early Stage Detection of Alzheimer’s Disease
ICA Test Proven to Quickly and Effectively Detect the Types of Cognitive Impairments That Traditionally Require Expensive and Invasive Techniques to Reveal
VANCOUVER, May 21, 2019 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN; FWB:1UB; OTCQB: CGNSF) announced that it has been selected to present new results from its ongoing research into the use of the company’s Integrated Cognitive Assessment (ICA) platform for the detection of early stage Alzheimer’s disease at the Alzheimer’s Society Annual conference 2019 at the Kia Oval, London on May 20th and 21st, 2019.
In a poster titled ‘Neural Speed of Visual Information Processing is Delayed in Early Stages of Alzheimer’s Disease‘, Cognetivity’s Chief Scientific Officer and Co-Founder, Dr. Seyed-Mahdi Khaligh-Razavi will present results detailing the ICA platform’s ability to detect subtle changes in the temporal dynamics of brain activity in subjects with Mild Cognitive Impairment (MCI) and mild Alzheimer’s disease (mild-AD).
Significantly, the research showed a delay in neural speed of visual information processing in participants with cognitive impairment (MCI and mild-AD) compared to age-matched healthy controls, suggesting that speed and accuracy of processing visual information are negatively affected in MCI and early stages of AD. This adds to the growing body of evidence on the suitability of visual information processing, as used by the ICA, for screening subtle cognitive impairments which can be detected before the onset of more severe cognitive symptoms in AD. The ICA has been shown to be able to detect changes in performance in those areas of the brain associated with the earliest signs of neurodegeneration in conditions such as AD.
This new data adds to the multiple existing validations of the ICA using clinical best practice neuropsychological tests, blood biomarkers, brain imaging functional MRI (fMRI) and now brain activity using high resolution electroencephalogram (EEG) data.
Cognetivity’s fast and simple to administer ICA test has consistently demonstrated its ability to accurately detect the types of cognitive impairment that have traditionally required more expensive, invasive and time-consuming techniques to detect.
“It is fantastic that we’ve been selected to present our latest groundbreaking research results at the Alzheimer’s Society conference in London, an event that brings together key players from industry and academia in the global fight against Alzheimer’s.” said Cognetivity’s CEO, Dr. Sina Habibi. “We have now validated our platform’s high performance against a number of more expensive, time consuming and invasive, yet well-established methods of dementia detection, and are continuing to progress quickly towards our goal of making the platform available to help as many people as possible.”
The Alzheimer’s Society Conference is a milestone annual event which attracts International and national dementia researchers/organisations, leaders within national health and social care and local and national government.
Notable attendees of the meeting include global pharmaceutical companies such as Biogen, academic researchers from leading institutions including Cambridge University and Imperial College London and senior representatives of the UK Government and National Health Service.
About Cognetivity Neurosciences Ltd.
Cognetivity is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA) for use in medical, commercial and consumer environments. Cognetivity’s ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain, potentially allowing early diagnosis of dementia. Cognetivity aims to develop the ICA through ongoing clinical studies to the market in North America, Europe and elsewhere in the world.
For more information please visit – www.cognetivity.com
ON BEHALF OF THE BOARD
Chief Executive Officer and Director
FORWARD LOOKING STATEMENTS:
The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information.
The Exchange does not accept responsibility for the adequacy or accuracy of this release
SOURCE Cognetivity Neurosciences Ltd
For further information: Email: firstname.lastname@example.org; For media enquiries contact: Josh Stanbury, Email: email@example.com